Nanoform and AstraZeneca Initiate Technology Evaluation


University of Helsinki

Nanoform is delighted to announce the initiation of a technology evaluation of Nanoform’s Proprietary CESSTM Technology across a range of AstraZeneca’s proprietary pharmaceutical products. Nanoform is a spin-out company from the University of Helsinki.

The initiation of this study is to assess the added value that Nanoform’s proprietary technology could deliver across the pharmaceutical value chain.

Commenting on the agreement, Edward Hæggström, CEO of Nanoform said:

“We have always believed that our technology has significant value to offer the Pharma industry, particularly in reducing clinical attrition rates by nanonizationTM to increase dissolution rates of poorly soluble APIs and overcome significant bioavailability challenges, as evidenced by the work conducted between us and our pharmaceutical partners.

Producing tailored nanoparticles

This is the first step of hopefully a long and successful relationship between our two companies and we look forward to working closely with AZ to support their early development needs and validating the value of our technology for their products.”

Read also: Nano­form shrinks drug particles



Department of Physics
Field of science
Physical sciences

/Public Release. The material in this public release comes from the originating organization and may be of a point-in-time nature, edited for clarity, style and length. View in full here.